Nodal histiocytic sarcoma with prominent eosinophilic infiltration: expression of eotaxin-2 on tumor cells.
Eosinophil
Eotaxin 2
Histiocytic sarcoma
LIGHT
PD-L1
Journal
Diagnostic pathology
ISSN: 1746-1596
Titre abrégé: Diagn Pathol
Pays: England
ID NLM: 101251558
Informations de publication
Date de publication:
12 Jan 2021
12 Jan 2021
Historique:
received:
09
10
2020
accepted:
21
12
2020
entrez:
13
1
2021
pubmed:
14
1
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Histiocytic sarcoma (HS) is a rare neoplasm showing morphological and immunophenotypic features of mature tissue histiocytes. We report a patient with nodal HS exhibiting prominent reactive eosinophilic infiltration. A 68-year-old man presented with intermittent left lower abdominal pain and weight loss over 3 months. A computed tomography scan revealed multiple abdominal nodules. Open biopsy of the mesenteric tumors was performed for definitive diagnosis. Histologically, the tumor was comprised of a diffuse noncohesive proliferation of pleomorphic large cells, including multinucleated cells. Neoplastic cells were positive for histiocytic markers (CD68, CD163, and LIGHT) and PD-L1 but lacked markers of Langerhans cells, follicular dendritic cells, and epithelial cells. Frequent reactive inflammatory cells were intermingled in the background. Interestingly, prominent eosinophilic infiltration was also noted. Spindle neoplastic cells were prone to be present around areas with little to no eosinophilic infiltration and exhibiting fibrosis and lymphatic vessel proliferation. Conversely, polygonal neoplastic cells were prone to be present around areas with relatively large amounts of eosinophilic infiltration without fibrosis or lymphatic vessel proliferation. Immunohistochemically, the tumor cells and reactive eosinophils expressed eotaxin-2 and eotaxin-3, respectively. We revealed that eotaxins induced the selective migration of eosinophils into tissues in this case. These eosinophils may affect the tumor remodeling and tumor biology characteristics of HS, such as fibrosis and lymphatic vessel proliferation.
Sections du résumé
BACKGROUND
BACKGROUND
Histiocytic sarcoma (HS) is a rare neoplasm showing morphological and immunophenotypic features of mature tissue histiocytes. We report a patient with nodal HS exhibiting prominent reactive eosinophilic infiltration.
CASE PRESENTATION
METHODS
A 68-year-old man presented with intermittent left lower abdominal pain and weight loss over 3 months. A computed tomography scan revealed multiple abdominal nodules. Open biopsy of the mesenteric tumors was performed for definitive diagnosis. Histologically, the tumor was comprised of a diffuse noncohesive proliferation of pleomorphic large cells, including multinucleated cells. Neoplastic cells were positive for histiocytic markers (CD68, CD163, and LIGHT) and PD-L1 but lacked markers of Langerhans cells, follicular dendritic cells, and epithelial cells. Frequent reactive inflammatory cells were intermingled in the background. Interestingly, prominent eosinophilic infiltration was also noted. Spindle neoplastic cells were prone to be present around areas with little to no eosinophilic infiltration and exhibiting fibrosis and lymphatic vessel proliferation. Conversely, polygonal neoplastic cells were prone to be present around areas with relatively large amounts of eosinophilic infiltration without fibrosis or lymphatic vessel proliferation. Immunohistochemically, the tumor cells and reactive eosinophils expressed eotaxin-2 and eotaxin-3, respectively.
CONCLUSION
CONCLUSIONS
We revealed that eotaxins induced the selective migration of eosinophils into tissues in this case. These eosinophils may affect the tumor remodeling and tumor biology characteristics of HS, such as fibrosis and lymphatic vessel proliferation.
Identifiants
pubmed: 33436014
doi: 10.1186/s13000-020-01061-4
pii: 10.1186/s13000-020-01061-4
pmc: PMC7805230
doi:
Substances chimiques
Biomarkers, Tumor
0
CCL24 protein, human
0
Chemokine CCL24
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP19K16577
Références
Blood. 1999 Sep 15;94(6):2065-71
pubmed: 10477736
Blood. 1999 Apr 15;93(8):2463-70
pubmed: 10194423
Mod Pathol. 2011 Nov;24(11):1421-32
pubmed: 21666687
Clin Cancer Res. 2007 Oct 1;13(19):5719-28
pubmed: 17908961
Laryngoscope. 2009 Jun;119(6):1053-9
pubmed: 19296494
Mod Pathol. 2019 Jun;32(6):830-843
pubmed: 30626916
J Leukoc Biol. 2019 Aug;106(2):345-358
pubmed: 30576000
Nat Rev Immunol. 2017 Dec;17(12):746-760
pubmed: 28891557
Oncotarget. 2017 Jan 17;8(3):5135-5148
pubmed: 28042950
Mod Pathol. 2005 May;18(5):693-704
pubmed: 15696128
Respir Res. 2001;2(3):150-6
pubmed: 11686879
Virchows Arch. 2009 Aug;455(2):187-90
pubmed: 19562369
Arch Pathol Lab Med. 2018 Nov;142(11):1322-1329
pubmed: 30407858
J Clin Exp Hematop. 2013;53(1):1-8
pubmed: 23801128
Haematologica. 2020 Apr;105(4):951-960
pubmed: 31439678
Neurology. 2014 Oct 14;83(16):1478-80
pubmed: 25209580
J Interferon Cytokine Res. 2005 Feb;25(2):82-91
pubmed: 15695929
Blood. 2018 Jan 11;131(2):265-268
pubmed: 29183888
Nat Rev Cancer. 2020 Oct;20(10):594-607
pubmed: 32678342
Pathol Int. 2008 Nov;58(11):701-5
pubmed: 18844935
Am J Dermatopathol. 2020 Apr;42(4):286-291
pubmed: 31567137
Curr Hematol Malig Rep. 2020 Aug;15(4):372-381
pubmed: 32394185
J Allergy Clin Immunol. 2003 Feb;111(2):227-42; quiz 243
pubmed: 12589338
J Leukoc Biol. 2013 Aug;94(2):213-22
pubmed: 23532518
Cell Death Dis. 2020 Feb 12;11(2):117
pubmed: 32051393